Post Profile






Related Posts


Pfizer drug delays lung cancer growth longer than Astra's Iressa: study

Health : Reuters: Health

(Reuters) - A targeted drug being developed by Pfizer Inc held advanced lung cancer in check longer than AstraZeneca's Iressa in newly diagnosed patients, but with a higher rate of side effects, according to data presented on Monday...

Shares in pharma giant AstraZeneca plunge more than 15% after lung cancer drug trial setback

Business & Finance : Business Insider: Clusterstock

LONDON — Shares in the pharmaceutical giant AstraZeneca are dropping fast on Thursday morning after the company announced that a trial of a new drug for treating lung cancer had not produced the expected results. In an update to the...

AstraZeneca lung cancer study fails in big setback for company

Health : Reuters: Health

LONDON (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

AstraZeneca aims to offset drug setback at big cancer congress

Health : Reuters: Health

LONDON (Reuters) - After last month's big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation next week when it unveils full details of two key clinical trials tackling the disease in diff...

AstraZeneca rebuilds cancer drug hopes with new lung data

Health : Reuters: Health

MADRID (Reuters) - Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset July's big clinical trial setback in the disease.

Comments


Copyright © 2016 Regator, LLC